演題詳細

一般口演 / Oral Session

一般口演 26 (Oral Session 26) :CML:臨床TKIその他

print

日程
2013年10月11日(金)
時間
15:25 - 16:25
会場
第7会場 / Room No.7 (ロイトン札幌 2F リージェント)
座長・司会
鳥本 悦宏 (Yoshihiro Torimoto):1
1:旭川医科大学病院 腫瘍センター
 
前へ戻る

Long term efficacy of TKI therapy for chronic myeloid leukemia; a single center experience

演題番号 : OS-1-132

中世古 知昭 (Chiaki Nakaseko):1、大和田 千桂子 (Chikako Ohwada):1、武内 正博 (Masahiro Takeuchi):1、清水 直美 (Naomi Shimizu):1,2、堺田 惠美子 (Emiko Sakaida):1、竹田 勇輔 (Yusuke Takeda):1、酒井 紫緒 (Shio Sakai):1,2、塚本 祥吉 (Shokichi Tsukamoto):1、川口 岳晴 (Takeharu Kawaguchi):1、武藤 朋也 (Tomoya Muto):1、山崎 敦子 (Atsuko Yamazaki):1、杉田 泰雅 (Yasumasa Sugita):1、横手 幸太郎 (Koutaro Yokote):3、井関 徹 (Tohru Iseki):2

1:Department of Hematology, Chiba University Hospital, Japan、2:Division of Transfusion Medicine and Cell Therapy, Chiba University, Japan、3:Department of Clinical Cell Biology and Medicine, Chiba University, Japan

 

Background: The introduction of tyrosine kinase inhibitors (TKIs) has significantly improved the prognosis of patients with CML. However, long-term efficacy of TKI therapy in Japanese patients is still unclear. Patients and methods: Patients with CML treated with TKIs in Chiba University Hospital were retrospectively analyzed. CMR was defined with M-BCR-ABL/ABL (IS) <0.0032% or M-BCR/ABL undetectable by TMA. Results: Between Jan 2002 and Mar 2013, 102 patients (male; 69, female 33) with CML were treated with TKIs. The median age at diagnosis was 49 years (range; 16-86) and median follow up (f/u) period was 5.5 years (0.2 - 20 years). Seventeen patients had a history of interferon treatment prior to TKIs. Imatinib was given as the first-line TKI in 87 patients, while 15 patients received 2nd TKIs (nilotinib 6, dasatinib 8, bosutinib 1) as the first-line. Among 87 patients with first-line imatinib, 35 patients still have received imatinib, while 47 patients have changed to 2nd TKIs due to adverse events or aiming CMR and subsequent discontinuation of TKIs. One patient died of blast crisis and 10-year OS was 98.6%. Among evaluable 100 patients, 91 patients (91%) achieved MMR and 64 patients (64%) achieved CMR. At the last f/u, 92 patients have continued TKIs and seven patients with CMR discontinued TKIs due to adverse events and six of them have continued CMR with a median f/u of 472 days (60-1328 days). Discussion: In the long-term f/u, CMR rate in Japanese patients and their survival are excellent. Their good adherence to TKIs may contribute to the effectiveness of TKIs.

前へ戻る